Please ensure Javascript is enabled for purposes of website accessibility

Why Biohaven Pharmaceutical Stock Is Tanking Today

By George Budwell - Jan 19, 2021 at 10:43AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Alzheimer's claims another drug candidate.

What happened

Shares of Biohaven Pharmaceutical Holding Co. (BHVN 0.69%) dropped by nearly 13% in pre-market action Tuesday morning. The drugmaker's shares are sinking following the release of disappointing phase 2/3 clinical trial results for its experimental Alzheimer's disease drug known as troriluzole.

Specifically, the company announced yesterday that troriluzole failed to beat out placebo at the 48-week mark in patients with mild to moderate Alzheimer's disease on two measures of cognitive decline: the Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 and the Clinical Dementia Rating Scale Sum of Boxes.  

Cross section of a human brain.

Image source: Getty Images.

As U.S. stock markets were closed Monday for Martin Luther King Jr. Day, Biohaven's shares are reacting to this news today. Although the drugmaker's shares have recovered to some degree since the start of trading today, they are still down by a noteworthy 8% as of 9:38 a.m. EST. 

So what

Alzheimer's disease has proven time and again to be a tough nut to crack. Despite numerous pharma companies pouring billions of dollars into research over the past two decades, there are still no disease-modifying drugs approved for this deadly neurodegenerative disorder. Biohaven's once-promising drug candidate appears set to join this long list of failures. That being said, the company did note that it is awaiting additional biomarker data in a subgroup of patients with early-stage disease before making a final call on troriluzole's fate. 

Now what

Should bargain hunters take advantage of this weakness in Biohaven's shares? The bottom line is that the biopharma had a lot riding on troriluzole's Alzheimer's indication. After all, the drug already posted less-than-stellar trial results in its two other high-value indications (obsessive-compulsive disorder and generalized anxiety disorder). As such, it might be a good idea to wait on additional data in this key indication before buying shares.  

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biohaven Pharmaceutical Holding Company Ltd. Stock Quote
Biohaven Pharmaceutical Holding Company Ltd.
$142.03 (0.69%) $0.98

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.